Overview: Two Generations of the Same Nootropic Peptide
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH). It has been studied for decades in Russian neuroscience literature as a nootropic and neuroprotective research compound acting largely through BDNF and NGF modulation.
N-Acetyl Semax Amidate (NASA) is a modified analog of Semax carrying two structural changes:
- N-terminal acetylation — an acetyl group (CH₃CO–) is attached to the free amino terminus of methionine.
- C-terminal amidation — the terminal carboxyl group is converted to an amide (–CONH₂) instead of a free acid.
Both modifications are designed to reduce enzymatic degradation and extend the peptide's functional half-life for research use.
Structural Comparison
| Property | Semax | N-Acetyl Semax Amidate |
|---|---|---|
| Core sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| N-terminus | Free amine (H–) | Acetylated (Ac–) |
| C-terminus | Free carboxyl (–OH) | Amidated (–NH₂) |
| Molecular weight | ~813 Da | ~854 Da |
| Net charge at pH 7 | Slightly acidic | More neutral |
| Enzymatic stability | Lower | Substantially higher |
Why Acetylation and Amidation Matter
Blocking Exopeptidase Cleavage
Small peptides in biological media are rapidly attacked by aminopeptidases (which cleave from the N-terminus) and carboxypeptidases (from the C-terminus). Standard Semax is vulnerable to both, contributing to its short measured half-life in plasma (often reported in minutes for intravenous exposure).
- N-terminal acetylation masks the free amine, blocking aminopeptidase recognition.
- C-terminal amidation removes the free carboxyl group required by many carboxypeptidases.
The combined effect is a peptide that resists degradation on both ends, extending the window in which it can interact with its research targets.
Impact on Bioavailability
Because most Semax research protocols use intranasal administration for nose-to-brain transport, degradation by nasal mucosal peptidases is a practical concern. In vitro studies of acetylated/amidated ACTH-fragment analogs consistently show:
- Longer residence time in mucosal tissue
- Increased fraction reaching central compartments
- More sustained downstream signaling (BDNF, NGF, dopaminergic tone)
Researchers frequently choose NASA when they want a longer-acting version of Semax without switching to a mechanistically different compound.
Pharmacological Profile: What Actually Changes
The receptor-level activity of NASA is qualitatively similar to Semax — it engages the same neurotrophic and monoaminergic pathways. What changes is duration and potency per dose, not the mechanism.
| Research parameter | Semax | N-Acetyl Semax Amidate |
|---|---|---|
| Onset (intranasal, research models) | Minutes | Minutes |
| Reported functional duration | ~2–4 hours | ~6–12+ hours |
| Typical research potency ratio | 1x reference | ~2–3x reference |
| BDNF/NGF modulation | Yes | Yes (more sustained) |
| Dopamine/serotonin signaling | Yes | Yes |
| Neuroprotective effect in ischemia models | Documented | Documented, extended window |
Research Dosing Comparison
For laboratory and in vitro research only. Not for human use.
- Semax: 200–600 mcg/day intranasally, typically divided into 2–3 administrations. Cycles of 10–14 days on / 7–14 days off are common in the literature.
- N-Acetyl Semax Amidate: 100–300 mcg per administration, once or twice daily, reflecting its extended duration. Total daily exposure is often lower than Semax on a mass basis.
Reconstitution: A 5 mg vial is typically dissolved in 1–2 mL of bacteriostatic water. Intranasal delivery requires a calibrated dropper or spray to ensure accurate microdosing.
When Researchers Choose Each Compound
Semax is often selected when:
- Studying the original ACTH(4–10) analog for direct literature comparison
- Short-acting exposures are preferred (pulsed dosing paradigms)
- Budget or availability favors the classical form
N-Acetyl Semax Amidate is often selected when:
- Longer receptor engagement is required per administration
- Fewer daily doses are logistically preferable in a protocol
- Studying sustained BDNF/NGF modulation or extended neuroprotective windows
- Comparing structurally stabilized analogs against the parent peptide
Storage and Handling
Both peptides are lyophilized powders. Store unopened vials at –20°C for long-term stability. After reconstitution, store at 2–8°C and use within 2–4 weeks. Protect from light and freeze-thaw cycles, which can degrade small peptides regardless of terminal modifications.
Common Research Questions
Is N-Acetyl Semax Amidate "stronger" than Semax? Not through a different mechanism — it engages the same pathways. It behaves as stronger in practice because more intact peptide reaches the target and stays there longer.
Can they be studied together? In research settings, they are usually compared head-to-head rather than combined, since they act on overlapping systems. Stacking would confound duration and dose–response analysis.
Does amidation alone give most of the benefit? Amidation alone improves C-terminal stability, but leaves aminopeptidase cleavage intact. The N-acetyl group is what closes the second degradation pathway — both modifications together produce the observed stability gain.
Research-Grade Semax and Related Peptides
Important Research Notice: All peptides sold by Amino Fuel Labs are strictly for laboratory research and in vitro use only. They are not FDA-approved for human consumption.
Explore related nootropic and neuroprotective research compounds including Semax, Selank, and our full research peptide catalog. Every batch ships with independent third-party COAs and fast domestic shipping.
This article is for educational and research purposes only.
